Using the Korean nationwide healthcare claims database, we constructed a retrospective cohort for prevalent pSS aged over 50 years. After enrollment between January 2012 and December 2014, patients were followed until the development of any malignancy, or until December 2015. Crude incidence rates of malignancies of pSS patients were calculated, and their standardized incidence ratios (SIRs) for malignancies were calculated compared to those in knee osteoarthritis (OA) patients.

Results

A total of 6,359 pSS and 5,476,302 knee OA patients were included in this study. During follow-up (19,474 person-years [PYs]), 310 cases of solid malignancy (158.8/10,000 PYs) and 47 cases of hematologic malignancies (23.5/10,000 PYs) were observed in pSS patients. The risks of overall (SIR 1.30, 95% CI 1.16-1.43), solid (SIR 1.16, 95% CI 1.03-1.29), and hematologic malignancies (SIR 4.80, 95% CI 3.43-6.17) were increased in pSS patients. There was an elevated risk of site-specific malignancy in non-Hodgkin's lymphoma (NHL, SIR 6.45, 95% CI 4.05-8.83), multiple myeloma (SIR 4.88, 95% CI 2.00-7.76), and oropharynx (SIR 4.16, 95% CI 1.90-6.42). The risk of lung cancer was increased only in male pSS patients (2.50, 95% CI 1.02-3.99), while the risk of thyroid cancer was increased in female patients (1.44, 95% CI 1.04, 1.84).

Conclusion

In patients with pSS over age 50, the risk of solid cancers such as oropharynx, thyroid, and lung cancers is also increased in addition to NHL.

CONFLICTS OF INTEREST

All authors have declared no conflicts of interest.

Supporting Information

REFERENCES

1Manoussakis MN, Moutsopoulos HM. Sjögren's syndrome. Otolaryngol Clin North Am. 1999; 32(5): 843-860.
10.1016/S0030-6665(05)70177-8
CAS PubMed Web of Science® Google Scholar
2Kruize AA, Hene RJ, van der Heide A, et al. Long-term followup of patients with Sjögren's syndrome. Arthritis Rheum. 1996; 39(2): 297-303.
10.1002/art.1780390219
CAS PubMed Web of Science® Google Scholar
3Sandhya P, Kurien BT, Danda D, Scofield RH. Update on pathogenesis of Sjögren's syndrome. Curr Rheumatol Rev. 2017; 13(1): 5-22.
10.2174/1573397112666160714164149
PubMed Web of Science® Google Scholar
4Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol. 2006; 18(2): 129-134.
10.1097/01.bor.0000209423.39033.94
PubMed Web of Science® Google Scholar
5Segal BM, Nazmul-Hossain AN, Patel K, Hughes P, Moser KL, Rhodus NL. Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011; 111(6): 673-680.
10.1016/j.tripleo.2011.01.040
PubMed Google Scholar
6Ienopoli S, Carsons SE. Extraglandular manifestations of primary Sjögren's syndrome. Oral Maxillofac Surg Clin North Am. 2014; 26(1): 91-99.
10.1016/j.coms.2013.09.008
PubMed Web of Science® Google Scholar
7Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev. 2017; 16(10): 1049-1057.
10.1016/j.autrev.2017.07.022
CAS PubMed Web of Science® Google Scholar
8Brito-Zeron P, Kostov B, Fraile G, et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol. 2017; 10(1): 90.
10.1186/s13045-017-0464-5
PubMed Web of Science® Google Scholar
9Alunno A, Leone MC, Giacomelli R, Gerli R, Carubbi F. Lymphoma and Lymphomagenesis in Primary Sjögren's Syndrome. Front Med (Lausanne). 2018; 5: 102.
10.3389/fmed.2018.00102
PubMed Web of Science® Google Scholar
10Nocturne G, Mariette X. Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol. 2015; 168(3): 317-327.
10.1111/bjh.13192
CAS PubMed Web of Science® Google Scholar
11Liang Y, Yang Z, Qin B, Zhong R. Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014; 73(6): 1151-1156.
10.1136/annrheumdis-2013-203305
PubMed Web of Science® Google Scholar
12Singh AG, Singh S, Matteson EL. Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2016; 55(3): 450-460.
PubMed Web of Science® Google Scholar
13Kim HJ, Kim KH, Hann HJ, et al. Incidence, mortality, and causes of death in physician-diagnosed primary Sjögren's syndrome in Korea: a nationwide, population-based study. Semin Arthritis Rheum. 2017; 47(2): 222-227.
10.1016/j.semarthrit.2017.03.004
PubMed Web of Science® Google Scholar
14Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61(6): 554-558.
10.1136/ard.61.6.554
CAS PubMed Web of Science® Google Scholar
15Park HR, Im S, Kim H, et al. Validation of algorithms to identify knee osteoarthritis patients in the claims database. Int J Rheum Dis. 2019; 22(5): 890-896.
10.1111/1756-185X.13470
PubMed Web of Science® Google Scholar
16Seo HJ, Oh I-H, Yoon S-J. A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea. Asian Pac J Cancer Prev. 2012; 13(12): 6163-6168.
10.7314/APJCP.2012.13.12.6163
PubMed Google Scholar
17Shin HR, Won YJ, Jung KW, et al. Nationwide cancer incidence in Korea, 1999–2001; first result using the national cancer incidence database. Cancer Res Treat. 2005; 37(6): 325-331.
10.4143/crt.2005.37.6.325
PubMed Google Scholar
18Lazarus MN, Robinson D, Mak V, Moller H, Isenberg DA. Incidence of cancer in a cohort of patients with primary Sjögren's syndrome. Rheumatology (Oxford). 2006; 45(8): 1012-1015.
10.1093/rheumatology/kei281
CAS PubMed Web of Science® Google Scholar
19Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006; 65(6): 796-803.
10.1136/ard.2005.041186
CAS PubMed Web of Science® Google Scholar
20Zhang W, Feng S, Yan S, et al. Incidence of malignancy in primary Sjögren's syndrome in a Chinese cohort. Rheumatology (Oxford). 2010; 49(3): 571-577.
10.1093/rheumatology/kep404
PubMed Web of Science® Google Scholar
21Weng MY, Huang YT, Liu MF, Lu TH. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjögren's syndrome in Taiwan. Ann Rheum Dis. 2012; 71(4): 524-527.
10.1136/annrheumdis-2011-200402
PubMed Web of Science® Google Scholar
22Oh CM, Won YJ, Jung KW, et al. Cancer Statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat. 2016; 48(2): 436-450.
10.4143/crt.2016.089
PubMed Web of Science® Google Scholar
23Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"–screening and overdiagnosis. N Engl J Med. 2014; 371(19): 1765-1767.
10.1056/NEJMp1409841
PubMed Web of Science® Google Scholar
24Xu Y, Fei Y, Zhong W, et al. The Prevalence and clinical characteristics of primary Sjögren's syndrome patients with lung cancer: an analysis of ten cases in China and literature review. Thorac Cancer. 2015; 6(4): 475-479.
10.1111/1759-7714.12216
PubMed Web of Science® Google Scholar
25Solans-Laque R, Lopez-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum. 2011; 41(3): 415-423.
10.1016/j.semarthrit.2011.04.006
PubMed Web of Science® Google Scholar
26Terpos E, Angelopoulou MK, Variami E, Meletis JC, Vaiopoulos G. Sjögren's syndrome associated with multiple myeloma. Ann Hematol. 2000; 79(8): 449-451.
10.1007/s002770000166
CAS PubMed Web of Science® Google Scholar
27Tazi I, Rachid M, Benchekroun S. Sjögren's syndrome associated with multiple myeloma. Singapore Med J. 2008; 49(8): e215-e216.
CAS PubMed Web of Science® Google Scholar
28Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H. Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 2008; 150(1): 49-52.
10.1016/j.jss.2007.09.020
PubMed Web of Science® Google Scholar
29Lun Y, Wu X, Xia Q, et al. Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg. 2013; 148(3): 396-402.
10.1177/0194599812472426
PubMed Web of Science® Google Scholar
30Lazarus MN, Isenberg DA. Development of additional autoimmune diseases in a population of patients with primary Sjögren's syndrome. Ann Rheum Dis. 2005; 64(7): 1062-1064.
10.1136/ard.2004.029066
CAS PubMed Web of Science® Google Scholar
31Zeher M, Horvath IF, Szanto A, Szodoray P. Autoimmune thyroid diseases in a large group of Hungarian patients with primary Sjögren's syndrome. Thyroid. 2009; 19(1): 39-45.
10.1089/thy.2007.0398
CAS PubMed Web of Science® Google Scholar
32Papiris SA, Maniati M, Constantopoulos SH, Roussos C, Moutsopoulos HM, Skopouli FN. Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann Rheum Dis. 1999; 58(1): 61-64.
10.1136/ard.58.1.61
CAS PubMed Web of Science® Google Scholar
33Wang HL, Zhou YM, Zhu GZ, Yang Z, Hua BJ. Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study. Clin Rheumatol. 2018; 37(1): 81-85.
10.1007/s10067-017-3676-8
PubMed Web of Science® Google Scholar

Citing Literature

Volume23, Issue9

September 2020

Pages 1240-1247

Risk of malignancy in Korean patients with primary Sjögren's syndrome

Abstract

Objectives

Methods

Results

Conclusion

CONFLICTS OF INTEREST

Supporting Information

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Risk of malignancy in Korean patients with primary Sjögren's syndrome

Abstract

Objectives

Methods

Results

Conclusion

CONFLICTS OF INTEREST

Supporting Information

REFERENCES

Citing Literature

References

Related

Information